Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Besse

Showing results (371-380 of 512) with videos related to

Pageof 52
Sort By:
Journal of Experimental & Clinical Cancer Research : CR|October 26, 2023
Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancerJérôme Cartry, Sabrina Bedja, Alice Boilève, et al.
The New England Journal of Medicine|June 1, 2026
Selpercatinib in Early-Stage <i>RET</i> Fusion-Positive Non-Small-Cell Lung CancerYi-Long Wu, Maximilian Hochmair, Yi Yang, et al.
Cell Reports. Medicine|November 18, 2020
CD103<sup>+</sup>CD8<sup>+</sup> T<sub>RM</sub> Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17Stéphanie Corgnac, Ines Malenica, Laura Mezquita, et al.
JCO Precision Oncology|September 11, 2020
Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non-Small-Cell Lung CancerJordi Remon, Ludovic Lacroix, Cecile Jovelet, et al.
European Journal of Cancer (Oxford, England : 1990)|March 7, 2020
Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapiesCapucine Baldini, Patricia Martin Romano, Anne-Laure Voisin, et al.
The Lancet. Oncology|September 15, 2022
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trialMary O'Brien, Luis Paz-Ares, Sandrine Marreaud, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 29, 2021
Central Nervous System Metastases in Thymic Epithelial Tumors: A Brief Report of Real-World Insight From RYTHMICJose Carlos Benitez, Marie-Ève Boucher, Eric Dansin, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2018
Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory diseaseFrançois-Xavier Danlos, Anne-Laure Voisin, Valérie Dyevre, et al.
Oncotarget|April 21, 2017
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective studyMichaël Duruisseaux, Benjamin Besse, Jacques Cadranel, et al.
European Journal of Cancer (Oxford, England : 1990)|March 14, 2022
ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMAJordi Remon, Benjamin Lacas, Roy Herbst, et al.
Pageof 52

Showing results (371-380 of 512) with videos related to

Sort By:
Pageof 52
Journal of Experimental & Clinical Cancer Research : CR|October 26, 2023
Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancerJérôme Cartry, Sabrina Bedja, Alice Boilève, et al.
The New England Journal of Medicine|June 1, 2026
Selpercatinib in Early-Stage <i>RET</i> Fusion-Positive Non-Small-Cell Lung CancerYi-Long Wu, Maximilian Hochmair, Yi Yang, et al.
Cell Reports. Medicine|November 18, 2020
CD103<sup>+</sup>CD8<sup>+</sup> T<sub>RM</sub> Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17Stéphanie Corgnac, Ines Malenica, Laura Mezquita, et al.
JCO Precision Oncology|September 11, 2020
Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non-Small-Cell Lung CancerJordi Remon, Ludovic Lacroix, Cecile Jovelet, et al.
European Journal of Cancer (Oxford, England : 1990)|March 7, 2020
Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapiesCapucine Baldini, Patricia Martin Romano, Anne-Laure Voisin, et al.
The Lancet. Oncology|September 15, 2022
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trialMary O'Brien, Luis Paz-Ares, Sandrine Marreaud, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 29, 2021
Central Nervous System Metastases in Thymic Epithelial Tumors: A Brief Report of Real-World Insight From RYTHMICJose Carlos Benitez, Marie-Ève Boucher, Eric Dansin, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2018
Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory diseaseFrançois-Xavier Danlos, Anne-Laure Voisin, Valérie Dyevre, et al.
Oncotarget|April 21, 2017
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective studyMichaël Duruisseaux, Benjamin Besse, Jacques Cadranel, et al.
European Journal of Cancer (Oxford, England : 1990)|March 14, 2022
ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMAJordi Remon, Benjamin Lacas, Roy Herbst, et al.
Pageof 52